Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowLong-Term Debt RepaymentsNet Cash FlowNet IncomeShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kezar Life Sciences (KZR) Cash from Financing Activities (2021 - 2025)

Historic Cash from Financing Activities for Kezar Life Sciences (KZR) over the last 5 years, with Q3 2025 value amounting to -$1.3 million.

  • Kezar Life Sciences' Cash from Financing Activities changed N/A to -$1.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$3.8 million, marking a year-over-year decrease of 343130.43%. This contributed to the annual value of $103000.0 for FY2024, which is 8385.58% down from last year.
  • Per Kezar Life Sciences' latest filing, its Cash from Financing Activities stood at -$1.3 million for Q3 2025.
  • Over the past 5 years, Kezar Life Sciences' Cash from Financing Activities peaked at $99.4 million during Q4 2021, and registered a low of -$1.3 million during Q3 2025.
  • For the 5-year period, Kezar Life Sciences' Cash from Financing Activities averaged around $14.0 million, with its median value being $185000.0 (2022).
  • Per our database at Business Quant, Kezar Life Sciences' Cash from Financing Activities soared by 2767375.89% in 2022 and then crashed by 236607.14% in 2025.
  • Quarter analysis of 5 years shows Kezar Life Sciences' Cash from Financing Activities stood at $99.4 million in 2021, then plummeted by 99.49% to $506000.0 in 2022, then tumbled by 88.34% to $59000.0 in 2023, then dropped by 20.34% to $47000.0 in 2024, then tumbled by 2876.6% to -$1.3 million in 2025.
  • Its Cash from Financing Activities was -$1.3 million in Q3 2025, compared to -$1.3 million in Q2 2025 and -$1.3 million in Q1 2025.